Valprol Cr 300 Tablet
Item requires a valid prescription
Manufactured By Intas Pharmaceuticals Limited
Composition Sodium Valproate 200mg + Valproic Acid 87mg
RS 86.96
MRP RS 102.31
(15% OFF)
Includes all taxes
Package SIZE
( 15 Tablet )
100% Authentic
Products
Free
Shipping*
Products
Return Policy
Description:
Sod Valproate is an antiepileptic which dissociates to the valproate ion in the GI tract and increased brain levels of gamma-aminobutyric acid (GABA).
Uses / Indications:
Valprol-CR 300 Tablet is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:
Epilepsy
Alcohol withdrawal
Mental illness
Depression disorders
Interactions / Warnings:
Do not take Valprol CR 300 Tablet 15's if you are allergic to any of its contents, if you have/ had liver problems, porphyria (blood disorder) or if you are susceptible to bleeding. Inform your doctor before taking Valprol CR 300 Tablet 15's if you have inflammation-like diseases, bone marrow damage or kidney problems. Talk to your doctor if you experience weakness, loss of appetite, lack of interest, recurrence or worsening of seizures, prolonged bleeding or abdominal pain while taking Valprol CR 300 Tablet 15's. Consult your doctor immediately if you experience suicidal tendency while taking Valprol CR 300 Tablet 15's. Please do not stop taking Valprol CR 300 Tablet 15's without consulting your doctor to avoid worsening of seizures. Do not take Valprol CR 300 Tablet 15's if you are pregnant as it could cause serious birth defects. If you are of child-bearing age, use effective contraception while taking Valprol CR 300 Tablet 15's. Consult your doctor before taking Valprol CR 300 Tablet 15's if you are breastfeeding. Valprol CR 300 Tablet 15's causes drowsiness and dizziness, so avoid driving unless you are alert. Avoid consuming alcohol along with Valprol CR 300 Tablet 15's as it could lead to increased risk of seizures. Care should be taken while giving Valprol CR 300 Tablet 15's to children below 3 years as there is a higher risk of liver intoxication during the first 6 months of treatment.